APA (7th ed.) Citation

Potestio, L., Martora, F., Raia, F., Lucagnano, G., Brescia, C., Torta, G., & Megna, M. Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study. Adis, Springer Healthcare.

Chicago Style (17th ed.) Citation

Potestio, Luca, Fabrizio Martora, Flavia Raia, Gioacchino Lucagnano, Claudio Brescia, Ginevra Torta, and Matteo Megna. Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study. Adis, Springer Healthcare.

MLA (9th ed.) Citation

Potestio, Luca, et al. Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study. Adis, Springer Healthcare.